Nonalcoholic fatty liver disease: Relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine

Alternative Medicine Review

Volumn 7, Issue 4, 2002, Pages 276-291

  Patrick, Lyn ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BETAINE; FATTY ACID; INSULIN; MAGNESIUM; PERHEXILINE; PHOSPHATIDYLCHOLINE; SELENIUM; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN B COMPLEX;

ABDOMINAL CRAMP; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; FATTY LIVER; HEPATITIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER MITOCHONDRION; METABOLIC DISORDER; NAUSEA; OBESITY; OUTCOMES RESEARCH; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; STEATOSIS; SYNDROME X; UNITED STATES;

ANTIOXIDANTS; BETAINE; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOTROPIC AGENTS; LIVER; MAGNESIUM; OBESITY; OXIDATIVE STRESS; VITAMIN E;

EID: 0036689875     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Insulin resistance and mitochondrial abnormalities in NASH: A cool look into a burning issue
2. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
3. Liver fibrosis in overweight patients
4. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients for up to 21 years
5. Nonalcoholic fatty liver disease
6. Nonalcoholic fatty liver disease: An agenda for clinical research
7. Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population
8. Liver pathology in morbidly obese patients with and without diabetes
9. Liver involvement in obese children: Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
10. The chronic disease of childhood obesity: The sleeping giant has awakened
11. Clinical hepatology: Profile of an urban, hospital-based practice
12. Prognosis in nonalcoholic steatohepatitis
13. Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity
14. Nonalcoholic steatohepatitis
15. Nonalcoholic steatohepatitis
16. Nonalcoholic steatohepatitis in children
17. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
18. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
19. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association
20. Nonalcoholic fatty liver disease. A feature of metabolic syndrome
21. NASH: From liver diseases to metabolic disorders and back to clinical hepatology
22. Syndrome X: 6 Years later
23. Diet and Syndrome X
24. Non-alcoholic fatty liver: Another feature of the metabolic syndrome?
25. Nonalcoholic steatohepatitis (NASH): A disease of emerging identity and importance
26. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study
27. Metabolic syndrome X: A review
28. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
29. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
30. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association
31. Association of non-alcoholic fatty liver disease with insulin resistance
32. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis
33. Steatohepatitis: A tale of two "hits"
34. Chronic ethanol treatment induces H2O2 production selectively in pericentral regions of the liver lobule
35. Mitochondrial adaptations to obesity-related oxidant stress
36. Mitochondria in steatohepatitis
37. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III)
38. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols
39. Diabetes mellitus and serum carotenoids: Findings from the Third National Health and Nutrition Survey
40. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: A four year follow up study in men
41. Pharmacological doses of vitamin E and insulin action in elderly subjects
42. Plasma lipid peroxidation and hyperglycemia: A connection through hyperinsulinemia?
43. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress
44. Etiopathogenesis of nonalcoholic steatohepatitis
45. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells
46. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis
47. Endotoxin, Kupffer cells and alcoholic liver injury
48. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole irrespective of protein-calorie malnutrition
49. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline
50. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: Its clinical significance
51. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
52. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers
53. Persistent hyperaminotransferasemia resolving after weight reduction in children
54. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
55. Hepatic effects of dietary weight loss in morbidly obese subjects
56. Prevalence of fatty liver in Japanese children and relationship to obesity: An epidemiological ultrasonographic survey
57. Altered ionic effects of insulin in hypertension: Role of basal ion levels in determining cellular responsiveness
58. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes
59. Hypomagnesmia, a risk factor in diabetic retinopathy
60. Magnesium levels in plasma erythrocytes and urine in patients with diabetes mellitus
61. Fasting plasma magnesium concentrations and glucose disposal in diabetes
62. Magnesium and glucose homeostasis
63. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects
64. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis
65. Study of antioxidant properties of metal aspartates
66. Erythrocytes from magnesium-deficient hamsters display an enhanced susceptibility to oxidative stress
67. Magnesium deficiency-induced cardiomyopathy: Protection by vitamin E
68. Vitamin E dietary supplementation inhibits transforming growth factor beta-1 gene expression in rat liver
69. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis
70. Effects of vitamin E and glutathione on glucose metabolism: Role of magnesium
71. Pharmacological doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients
72. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
73. Plasma transforming growth factor-b1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study
74. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor-β1
75. Increased transforming growth factor-β1 gene expression in human liver disease
76. Dietary lecithin, antioxidant and vitamin B complex (LAB) decrease hepatic steatosis in patients with nonalcoholic steatohepatitis (NASH)
77. Controlled study using multiple-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis
78. Therapy for HbsAg-positive chronically active hepatitis
79. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis B and C: A multicenter, double-blind, placebo-controlled trial
80. The lipotrophic factors
81. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis
82. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
83. Plasma total homocysteine levels are higher in nonalcoholic steatohepatitis
84. Homocystinuria - The effects of betaine in the treatment of patients not responsive to pyridoxine
85. Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency
86. Dietary betaine promotes generation of hepatic s-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
87. Homocysteine metabolism: Nutritional modulation and impact on health and disease
88. S-adenosylmethionine: A control switch that regulates liver function
89. Liver morphology and function tests in obesity and during total starvation
90. Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease